logo-loader
viewArecor

Full interview: Arecor completes dosing in its Phase I clinical trial and secures key partnership

Arecor's Sarah Howell tells Proactive London's Andrew Scott they've now completed dosing and patient visits in the Austria-based phase I study of its ultra-rapid acting insulin candidate, AT247, with results expected by the end of the year.

They've also signed a research, development and commercialisation deal with JDRF - the world's leading type 1 diabetes research charity.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex gets FDA Fast Track for its Oncoprex combination...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has been granted Fast Track Designation by the FDA for its Oncoprex immunogene therapy to treat lung cancer. Varner says the FDA validation is important, and gives the company more opportunities to meet with the...

2 days, 3 hours ago

2 min read